Roche’s vision-loss drug Vabysmo gets EU nod

The approval from the European Commission--the EU's executive arm--comes after four phase-3 studies showing vision gains and anatomical improvements in patients given the drug, Roche said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.